Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Cijeli opis

Bibliografski detalji
Glavni autori: Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Format: Članak
Jezik:English
Izdano: Wiley 2019-10-01
Serija:Cancer Medicine
Teme:
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non‐small cell lung cancer
treatment duration
Online pristup:https://doi.org/10.1002/cam4.2420

Internet

https://doi.org/10.1002/cam4.2420

Slični predmeti